Key result
NOACs were similar to LMWH in preventing VTE and VTE-related deaths in overweight (OR 0.64, P=0.19) and obese (OR 0.76, P=0.43) postarthroplasty patients, though apixaban was superior in obesity.
Why the study?
Do fixed-dose NOACs prevent VTE and VTE-related deaths in overweight and obese postarthroplasty patients compared to LMWH?
Meta-Analysis (n=16,674)
Do fixed-dose NOACs prevent VTE and VTE-related deaths in overweight and obese postarthroplasty patients compared to LMWH?
Odds Ratio: 0.64
p-value: p=0.19
Fixed-dose apixaban appears superior to LMWH for VTE prophylaxis in obese postarthroplasty patients, whereas dabigatran 150 mg may be less effective.
No takes yet. Share an insight, caveat, or question.
Apixaban may be preferred over LMWH for VTE prophylaxis in obese postarthroplasty patients; extends agent-specific NOAC evidence in obesity.
Pathak et al. (2015) conducted a meta-analysis in Venous thromboembolism in overweight and obese postarthroplasty patients (n=16,674). New oral anticoagulants (NOACs) vs. Low-molecular-weight heparin (LMWH) was evaluated on VTE and VTE-related deaths (OR 0.64, p=0.19). NOACs were similar to LMWH in preventing VTE and VTE-related deaths in overweight (OR 0.64, P=0.19) and obese (OR 0.76, P=0.43) postarthroplasty patients, though apixaban was superior in obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: